- Home
- GMAB
GMAB
Genmab A/S ADS
as of 01-05-2026 3:42pm EST
$31.73
$0.02
-0.05%
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
| Founded: | 1999 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 20.6B | IPO Year: | N/A |
| Target Price: | $40.40 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 25.10 | EPS Growth: | 132.41 |
| 52 Week Low/High: | $17.23 - $33.96 | Next Earning Date: | 02-11-2026 |
| Revenue: | $3,845,670,022 | Revenue Growth: | 29.57% |
| Revenue Growth (this year): | 24.85% | Revenue Growth (next year): | 16.51% |
AI-Powered GMAB Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.16%
75.16%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Genmab A/S ADS News
GMAB Breaking Stock News: Dive into GMAB Ticker-Specific Updates for Smart Investing
MT Newswires
Genmab Faces 'Transformative' Year Ahead With Pivotal Trial Readouts, Truist Securities Says
📈
AI Sentiment
Highly Positive
9/10
Investing.com
SoftBank completes $40 billion investment in OpenAI, CNBC says
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
ADENTRA Announces Normal Course Issuer Bid
Investor's Business Daily
This Company Just Announced Long-Term Contracts For Nuclear Power Amid Rosy Outlook For This Commodity
Compare GMAB vs Leading Stocks
See how GMAB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GMAB Genmab A/S ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.